Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03280225 · ClinicalTrials.gov registry record
REACH VET Implementation Program Evaluation
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 28
- Enrollment target
NCT03280225: Completed study, sponsored by VA Office of Research and Development.
NCT03280225 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03280225 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The VA's Office of Mental Health and Suicide Prevention implemented an new program to increase suicide prevention outreach for Veterans at highest risk for suicide. Using a statistical model, REACH VET, short for Recovery Engagement and Coordination for Health - Veterans Enhanced Treatment, uses information from Veterans' health records to identify those who are at a higher risk for suicide, hospitalization, illness, or other negative outcomes. Once a Veteran is identified, his or her VA mental health or primary care provider reaches out to check on the Veteran's well-being and review their treatment plan to determine if enhanced care is needed. The goal of the current study was to evaluate the implementation of this program. The objectives of this evaluation were to evaluate how well this program is put into place using an implementation strategy called virtual external facilitation, and to collect data about the cost of the program and the strategy.
Primary Outcome
The average percentage of eligible Veterans across all 23 participating sites having a coordinator assigned within 2 weeks of the monthly REACH VET report being released during the 6 month post-implementation period.
Interventions
- OTHER External facilitation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2020-12-31 |
What the finished NCT03280225 record still lists
NCT03280225 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which External facilitation is the first listed.
NCT03280225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03280225 about?
NCT03280225 is a clinical study titled "REACH VET Implementation Program Evaluation". The VA's Office of Mental Health and Suicide Prevention implemented an new program to increase suicide prevention outreach for Veterans at highest risk for suicide. Using a statistical model, REACH VET, short for Recovery Engagement and Coordination for Health - Veterans Enhanced Treatment, uses inf...
What is the current status of trial NCT03280225?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2017-09-18. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03280225?
The interventions under investigation include: External facilitation (OTHER).
Who is sponsoring clinical trial NCT03280225?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI